Cholesterol Drugs Linked To Eye Damage, JAMA Study Confirms Anew.
By Sayer Ji 27th September 2013. Find Full Article Here:-
Statin-induced eye damage will be a surprising finding to some, especially to statin drug advocates who have argued that the purported ‘antioxidant’ effects of statins ‘may slow the natural aging process of the lens.’ This latter, strictly theoretical benefit is increasingly being disproved by the biomedical literature. In fact, last year, we reported in an article titled, “Blind To The Truth: The Eye-Damaging Effects of Statins,” on findings published in Optometry and Vision Science, revealing that statin drugs users have a 48% higher risk of pathological eye lens changes commonly associated with cataract formation.
A cataract is a clouding of the lens of the eye which leads to a decrease in vision, and is a leading cause of blindness in the world. The most commonly identified causes are aging, trauma and excessive UV radiation exposure, along with a still poorly understood genetic component. While there is preclinical evidence that the opacity of the lens can be reversed through natural substances such as wheatgrass, the most common conventional approach is to treat the condition with surgery, which does nothing to mitigate or undo the underlying causes.
Researchers at San Antonio Military Medical Center, San Antonio Texas, compared the risks for development of cataracts between statin users and nonusers, using a military health care system database. The study design was described as follows:
Based on medication fills during fiscal year 2005, patients were divided into 2 groups: (1) statin users (received at least a 90-day supply of statin) and (2) nonusers (never received a statin throughout the study). Among 46 249 patients meeting study criteria, we identified 13 626 statin users and 32 623 nonusers.
The main results were reported as follows:
For our primary analysis, we matched 6972 pairs of statin users and nonusers. The risk for cataract was higher among statin users in comparison with nonusers in the propensity score-matched cohort (odds ratio, 1.09; 95% CI, 1.02-1.17). In secondary analyses, after adjusting for identified confounders, the incidence of cataract was higher in statin users in comparison with nonusers (odds ratio, 1.27; 95% CI, 1.15-1.40). Sensitivity analysis confirmed this relationship.
In other words, the risk for cataract was between 9% and 27% higher in statin users, leading the study authors to conclude: “The risk for cataract is increased among statin users as compared with nonusers. The risk-benefit ratio of statin use, specifically for primary prevention, should be carefully weighed, and further studies are warranted.”